Financial Performance - The company recorded a total revenue of RMB 2,103.44 million for the year ended December 31, 2022, representing an increase of RMB 353.32 million or 20.19% compared to the previous year[2]. - The net profit attributable to shareholders was approximately RMB 180.47 million, a decrease of 48.76% compared to the previous year, while the net profit excluding non-recurring items was RMB 158.75 million, down 51.60%[2]. - Total revenue for the year 2022 reached RMB 2,103,438 thousand, a 20.2% increase from RMB 1,750,116 thousand in 2021[23]. - The company reported a profit attributable to ordinary equity holders of approximately RMB 180.47 million, a decrease of about RMB 171.76 million or 48.76% from RMB 352.23 million in 2021[85]. - The overall gross profit margin for the reporting period was 68.79%, down from 71.98% in 2021, primarily due to lower margins from newly acquired businesses[77]. Revenue Breakdown - Revenue from mainland China was RMB 1,699,078 thousand in 2022, up from RMB 1,542,592 thousand in 2021, representing a growth of 10.1%[23]. - The company’s revenue from ophthalmic products was RMB 765,969 thousand in 2022, compared to RMB 670,969 thousand in 2021, reflecting a growth of 14.2%[25]. - The company’s revenue from Europe increased significantly to RMB 140,814 thousand in 2022 from RMB 66,965 thousand in 2021, marking a growth of 109.5%[23]. - The company’s revenue from the United States rose to RMB 103,717 thousand in 2022, up from RMB 82,918 thousand in 2021, indicating a growth of 25.0%[23]. - The revenue from optical materials business was RMB 179.46 million, an increase of approximately RMB 18.12 million, with a growth rate of 11.23%[60]. Expenses and Costs - Research and development expenses amounted to approximately RMB 182.19 million, an increase of RMB 14.59 million or about 8.71% year-on-year, accounting for 8.66% of total revenue[2]. - Selling and distribution expenses increased to approximately RMB 679.53 million, up by about RMB 67.19 million or 10.97% from RMB 612.34 million in 2021[79]. - Administrative expenses rose to approximately RMB 405.30 million, an increase of about RMB 119.21 million or 41.67% compared to RMB 286.09 million in 2021[80]. - The cost of goods sold increased significantly to RMB 656,515,000 in 2022 from RMB 490,370,000 in 2021, representing a rise of about 33.9%[29]. Assets and Liabilities - Non-current assets increased to RMB 3,360.28 million from RMB 3,237.77 million in the previous year[6]. - Current assets decreased to RMB 3,532.12 million from RMB 3,712.59 million in the previous year[6]. - Total liabilities increased to RMB 990.02 million from RMB 890.07 million in the previous year[7]. - The total equity attributable to shareholders decreased to RMB 5,902.38 million from RMB 6,060.29 million in the previous year[8]. - The group’s total liabilities as of December 31, 2022, are approximately RMB 990.02 million, with a debt-to-asset ratio of 14.36%, an increase of 1.55 percentage points from 12.81% in 2021[91]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 0.4 per share (tax included) for the year ended December 31, 2022[2]. - Proposed final dividend for 2022 is RMB 0.40 per share, totaling RMB 68,508,400, while the final dividend for 2021 was RMB 0.70 per share, totaling RMB 123,075,000[32][33]. - The company repurchased 1,692,100 H-shares during the year ended December 31, 2022, and canceled these shares on July 7, 2022[9]. - The company repurchased 2,859,000 H-shares at a total cost of approximately HKD 84,224,000, completing the cancellation of these shares on February 14, 2023[54]. Research and Development - The company completed clinical trials for its fourth-generation organic cross-linked hyaluronic acid products and is now in the registration application phase[2]. - The company is focused on expanding its ophthalmic and medical aesthetics product lines through innovation and R&D investment[57]. - The company is currently evaluating the impact of the new accounting standards on existing loan agreements, with no significant effects anticipated[21]. Market Position and Strategy - The company maintained its position as the largest producer of ophthalmic viscoelastic devices in China, with a market share of 50.83%[58]. - The company has exclusive distribution rights for high-end orthokeratology lenses in mainland China, enhancing market share and product variety[62]. - The company aims to enhance its core competitiveness through the integration of acquired enterprises and maximize operational efficiency in 2023[75]. - The company is leveraging its competitive advantages in medical biomaterials to lead the domestic micro-injection market for hyaluronic acid products[68]. Employee and Compensation - The total number of employees in the group as of December 31, 2022, is 1,990, with a breakdown of 701 in production, 344 in R&D, 599 in sales and marketing, 86 in finance, and 260 in administration[87]. - The total employee compensation for the reporting period is approximately RMB 533.22 million, an increase of about RMB 118.84 million from RMB 414.38 million in 2021, primarily due to the inclusion of Nanpeng Optics and the full-year performance of Ouhua Group[87].
昊海生物科技(06826) - 2022 - 年度业绩